## UTHR: United Therapeutics Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.44 indicates fundamental undervaluation. Quality metrics strong (ROE 20%, ROA 13%). Caution: declining volume (48% of avg), momentum weakening (-2.8% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($473.95)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 1
- **Sentiment:** Bearish (Bullish: 0, Bearish: 0)

**1. United Therapeutics Insider Sold Shares Worth $11,572,963, According to a Recent SEC Filing**
- Source: marketscreener.com | 20251230T040929 | Somewhat-Bearish | Relevance: 100%
- An insider at United Therapeutics (UTHR) has sold shares valued at $11,572,963, according to a recent SEC filing. This transaction, dated December 29, 2025, is one of several insider share sales reported for the company in recent weeks. United Therapeutics Corporation is a pharmaceutical company that markets commercial therapies for pulmonary arterial hypertension and an oncology product.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 23 ($13.76M) |
| Sells | 66 ($41.22M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Blackrock Inc.: 12.4% (+0.4%)
- Vanguard Group Inc: 10.3% (-0.7%)
- Renaissance Technolo: 5.1% (+2.6%)
- Avoro Capital Adviso: 4.7% (-14.7%)
- State Street Corpora: 4.5% (-11.3%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-2.8% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $41M sold (66 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.44 suggests fair value with growth premium. Forward P/E 17.4x stretched relative to 5% growth. Quality metrics strong (ROA 13%, margin 41%). Balance sheet: strong liquidity (6.4x), low leverage (D/E 0.12). Insider selling cluster ($41.2M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $22.4B |
| Beta | 0.86 |
| 52W Range | $266.98 - $519.99 |
| Short Interest | 6.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.44 |
| Forward P/E | 17.4 |
| Current P/E | 18.3 |
| YoY Growth | 5.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 2.6% to -0.2% (-2.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.2pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.36x) but short-term weakness (below SMA20). MACD histogram bearish (-1.69), momentum weakening. RSI neutral at 53. Volume at 48% of 20MA suggests lack of conviction. OFD pattern: -MTL (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.23% (CS: 40) | Neutral |
| RSI_14 | 53.1 | Neutral |
| MACD Histogram | -1.69 | Bearish |
| vs SMA20 | 0.999x | Below |
| vs SMA50 | 1.053x | Above |
| vs SMA200 | 1.363x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $496.19
- **Stop Loss:** $473.95 (4.5% risk)
- **Target:** $540.67 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 59
- **Position Value:** $29,275.21
- **Portfolio %:** 29.28%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with balanced risk signals and moderate market participation. VIX at 14.33 indicates calm conditions, while positive yield curve (+59bps) and stable economic data support continued expansion. Year-end positioning and Fed uncertainty create near-term caution, but no systemic risks evident.*

### Earnings

**Next:** 2026-02-25 (Est: $6.88)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $6.96 | $7.16 | +2.9% |
| 2025Q2 | $6.94 | $6.41 | -7.6% |
| 2025Q1 | $6.28 | $6.63 | +5.6% |
| 2024Q4 | $6.27 | $6.19 | -1.2% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*